Kodiak Sciences Inc. KOD
Updated: 17 Jun 2026
No signal published yet
We already track Kodiak Sciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Kodiak Sciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Kodiak Sciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, Kodiak announced positive topline results from its Phase 3 GLOW2 study of Zenkuda in diabetic retinopathy, demonstrating significant superiority over sham treatment. The company reported a cash position of $169.5 million as of March 31, 2026, and is advancing toward its first multi-indication Biologics License Application submission.
What Firelda Watch includes for Kodiak Sciences Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Kodiak Sciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Kodiak Sciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more